Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPD 168568 dihydrochloride
说明： Potent and selective D4 antagonist
化学名： 3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-one dihydrochloride
纯度： ≥98% (HPLC)
生物活性 for PD 168568 dihydrochloride
PD 168568 dihydrochloride is a potent and selective dopamine D4 receptor antagonist (Ki values are 8.8 and 1842 nM at D4 and D2 receptors respectively). Reverses amphetamine-stimulated locomotion in vivo and is orally active.
技术数据 for PD 168568 dihydrochloride
| 分子量 | 422.39 |
| 公式 | C22H27N3O.2HCl |
| 储存 | Desiccate at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1782532-06-2 |
| PubChem ID | 56972231 |
| InChI Key | RMNWLEGGYCVHFD-UHFFFAOYSA-N |
| Smiles | CC1=C(C)C=CC(N2CCN(CCC(N4)C3=CC=CC=C3C4=O)CC2)=C1.Cl.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for PD 168568 dihydrochloride
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 21.12 | 50 | |
| DMSO | 42.24 | 100 |
制备储备液 for PD 168568 dihydrochloride
以下数据基于产品分子量 422.39。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.37 mL | 11.84 mL | 23.67 mL |
| 5 mM | 0.47 mL | 2.37 mL | 4.73 mL |
| 10 mM | 0.24 mL | 1.18 mL | 2.37 mL |
| 50 mM | 0.05 mL | 0.24 mL | 0.47 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for PD 168568 dihydrochloride
参考文献 for PD 168568 dihydrochloride
参考文献是支持产品生物活性的出版物。
Belliotti et al (1998) Isoindolinone enantiomers having affinity for the DA D4 receptor. Bioorg.Med.Chem.Lett. 8 1499 PMID: 9873377
If you know of a relevant reference for PD 168568 dihydrochloride, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: PD 168568 dihydrochloride, PD 168568 dihydrochloride supplier, Potent, selective, D4, antagonists, Dopamine, Receptors, dopaminergic, PD168568, dihydrochloride, 3529, Tocris Bioscience
1 篇 PD 168568 dihydrochloride 的引用文献
引用文献是使用了 Tocris 产品的出版物。 PD 168568 dihydrochloride 的部分引用包括：
Ward et al (2017) Intravitreally-administered DA D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews. Vis Neurosci 34 E003 PMID: 28304244
您是否知道使用了 Tocris PD 168568 dihydrochloride 的优秀论文？ 请告知我们.
PD 168568 dihydrochloride 的评论
目前没有该产品的评论。 Be the first to review PD 168568 dihydrochloride and earn rewards!
Have you used PD 168568 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.